Botched Berry integration or a cyclical volume leg-down while carrying 4.9× net-debt/EBITDA
One-line thesis. Amcor is a newly-doubled global packaging giant (the April-2025 Berry Global merger) that trades cheap (~11× forward earnings) and pays a ~5.75% dividend, but the "growth" you see in the headlines is acquired, not organic — volumes are actually down ~1.5% YoY — and the company is carrying ~4.9× net-debt/EBITDA. It is a synergy-and-deleveraging turnaround, not a compounder, so we rate it Watch until the integration proves out.
◆ Synthos call — HoldAMCR is a solid business largely reflected at ~$48 — fine to keep, no reason to chase; it gets interesting again below ~$41.
Downside Risk (lower = safer)
6/10 · High
Cheap on forward EPS (~11×) & low beta 0.64, but 4.9× net-debt/EBITDA post-Berry and a 5.75% dividend at a distorted payout are the overhang.
Growth Quality
4/10 · Moderate
Growth is merger-manufactured, not organic — volumes ~1.5% LOWER YoY; 18% gross margin, single-digit ROIC, low-single-digit organic outlook.
Exponential Potential
3/10 · Low
A mature, cyclical packaging consolidator in a low-growth end market — synergy-and-deleveraging story, not an exponential; TAM is not the constraint, growth is.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 7%/yrTo justify today’s $45, earnings would have to compound roughly 7% a year for 10 years (9% discount rate). Analysts forecast ~28%/yr, so the market is pricing in LESS than what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
Amcor makes packaging — the flexible wrappers, films, bottles, and containers around food, drinks, medicine, and household products. It is one of the two or three biggest packaging companies on earth, and in April 2025 it got much bigger by merging with a rival, Berry Global. So the company today is roughly double the size it was two years ago.
Is the stock cheap or expensive? On the surface it looks cheap — you pay about $11 for every $1 of expected yearly profit (most big companies cost far more), and it pays a fat ~5.75% dividend, like a savings account that also owns factories. The catch: it's cheap for reasons. Packaging is a slow, up-and-down business, the amount of stuff Amcor actually shipped last quarter was slightly lower than a year ago, and the company borrowed a lot of money to buy Berry — so it owes roughly five years of profits in debt.
Our verdict is Watch — meaning interesting but wait. It could work out as a boring, high-dividend "value" stock if management successfully blends the two companies and pays down debt. But there's nothing here that grows fast, and the debt makes a bad year hurt more.
Here's what our three scores mean in everyday terms:
Downside Risk 6/10 (a bit above average). The stock itself is stable and cheap, but the heavy debt load and the big dividend it must keep funding raise the stakes if business softens.
Growth Quality 4/10 (below average). It's a solid, real business, but it barely grows on its own — the recent growth was bought, not earned.
Exponential Potential 3/10 (low). Packaging is a mature, low-growth industry. This is not the kind of company that doubles quickly.
The one big worry: merging two giant companies is hard. If the Berry integration goes sideways — or if a normal industry downturn hits while Amcor is still loaded with debt — the dividend and the stock could both suffer.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLY (sector)), set to 100 a year ago
Solid = AMCR · dashed = S&P 500 · dotted = XLY (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$45.00
Market cap$21B
P/E trailing2×
P/E FY26E / FY27E11× / 10×
EV / Sales1.6×
EV / EBITDA11.7×
Gross margin17.9%
Net margin3.1%
Dividend yield5.75%
Beta0.636
52-wk range$37 – $51
RSI(14)82
50 / 200-DMA$40 / $42
12-mo return+-5% (SPY +21%)
Street target$48 ($41–$54)
Analyst grades9 Buy · 2 Hold · 2 Sell
FMP ratingB-
Next earnings2026-08-05
What the experts actually said 0 traceable claims on AMCR · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
Amcor plc (NYSE: AMCR) is a global packaging manufacturer headquartered in Zürich, Switzerland, with ~77,000 employees. It designs and produces flexible and rigid packaging for food, beverage, pharmaceutical/medical, personal-care, and household end-markets. Fiscal year ends June 30.
The defining event is the all-stock merger with Berry Global, which closed April 30, 2025. Legacy Amcor was the accounting acquirer, so the reported FY2025 annual income statement (revenue $15.0B, ~318M shares) captures only ~2 months of Berry — it understates the combined company. The run-rate picture is in the recent quarters: ~$5.9B revenue per quarter and ~463M shares outstanding (post the 1-for-5 reverse stock split effected January 14, 2026). Trailing-twelve-months combined revenue is ~$22.2B. This split-history and merger discontinuity is the single biggest thing to understand before reading any per-share number here.
Revenue mix (FY2025 reported, from filings — pre-full-Berry):
By segment: Flexibles $10.87B (72%) · Rigid Packaging $4.14B (28%). Flexibles (films, wraps, pouches) is the higher-margin, more-defensive core; Rigid (bottles, containers, closures) is more commoditized and cyclical. (Post-Berry the combined mix tilts further toward Flexibles and consumer/healthcare.)
By geography: North America $7.19B (48%) · Europe $4.32B (29%) · Latin America $1.79B (12%) · Asia Pacific $1.70B (11%). A genuinely global, diversified footprint — no single region dominates catastrophically, which dampens (but does not remove) cyclicality.
2. The expert thesis — why the panel is bullish (traceable)
There is no expert coverage of Amcor in the Synthos knowledge base.total_claims = 0, net_bullish_voices = 0, and the top array is empty. None of the tracked investor/operator voices Synthos distills have a signed, dated view on AMCR.
That means there is no conviction-track thesis to cite — and honesty is the product, so we will not manufacture one. This verdict is entirely fundamentals- and quant-driven: the financial statements, the analyst-estimate consensus (FMP), management's own dated guidance (§9, half-weighted), and the technical/quant read below. Where the Street has a view we show it as context, not as our anchor.
Reader takeaway: treat this note as a rigorous read of the numbers, not as an expert-endorsed high-conviction call. The absence of KB coverage is itself information — Amcor is not a name the tracked exponential-hunters are talking about, consistent with our read that it is a mature value/income name rather than a forward compounder.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
6 · Moderate-High
Cheap (~11× fwd EPS) and low beta (0.64) cushion the downside, but net-debt/EBITDA ~4.9× post-Berry and a ~5.75% dividend the company must keep funding raise the stakes; a cyclical volume down-leg would bite.
Growth Quality
4 · Below-Average
Headline growth is merger-manufactured — organic volumes were ~1.5% LOWER YoY in Q3. 18% gross margin, ~4% ROIC, single-digit organic outlook. Real cash generator, but not a quality compounder.
Exponential Potential
3 · Low
A mature, cyclical packaging consolidator in a low-growth end-market. The story is synergies + deleveraging, not acceleration. TAM is not the binding constraint — growth is.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them. All EPS figures are adjusted (non-GAAP) to match how the Street and management frame this name; GAAP is depressed by acquisition/integration charges.
Case
Key assumptions
Fair value
Bull
Berry synergies land at/above the $270M FY26 target and build toward management's multi-year run-rate; deleveraging proceeds; end-market volumes recover. FY27E adj. EPS beats to ~$4.75; the market re-rates a de-levered compounder to ~13×.
~$62 (+38%)
Base(our anchor)
Guidance roughly holds — FY26 adj. EPS ~$4.00, FY27E ~$4.33 (consensus); a leveraged-but-stabilizing packager earns a modest ~11× with the ~5.75% yield doing much of the total-return work.
~$48 (+7%)
Bear
Integration friction, a cyclical volume leg-down, or FX/raw-material squeeze; synergies slip and deleveraging stalls. FY27E adj. EPS misses to ~$3.80; multiple de-rates to ~9×, dividend growth freezes.
~$34 (−24%)
Synthos fair value = the base case, ~$48 (+7%), with the full $34–$62 span as the honest range. This anchor sits essentially on top of the Street's $47.75 consensus — appropriate for a name where we have no differentiated expert edge and the value is in the numbers, not in a variant view. This is a tracked call — the Forecaster Scorecard grades it once it matures. Note the total-return math leans on the dividend: ~7% price upside plus ~5.75% yield is a ~13% one-year total-return if the base case holds — respectable, but income-driven, not growth-driven.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). AMCR is neither — it is a mature, cyclical consolidator:
Forward growth: on the combined base, consensus revenue is roughly flat-to-low-single-digit — ~$23.1B FY26E → ~$23.8B FY27E → ~$24.1B FY28E (a ~1–3% CAGR). Adjusted EPS grows faster (~$4.00 → ~$4.52 by FY29E, a high-single-digit CAGR) but that is synergy- and deleveraging-driven, not demand-driven.
Acceleration (the 2nd derivative) is the wrong sign for organic volume: management stated Q3 volumes were ~1.5% lower than the combined prior-year base. The impressive +77% headline revenue is entirely the Berry acquisition, not the business speeding up. Once you annualize Berry, organic growth is flat-to-negative.
Room to run: the constraint here is not TAM. Global packaging is a large, established market, but it grows with GDP and consumer volumes, not exponentially. At ~$20.8B market cap Amcor is not "small with room" in a growth sense — it is already one of the largest players in a slow industry, so the multibagger path does not exist.
Reinvestment runway: capex is modest (~2% of sales) and much of free cash flow is committed to the dividend and to paying down merger debt — the opposite of a high-reinvestment compounder.
Exponential Potential: Low (3/10). Own AMCR, if at all, for cheap cash flow, a high dividend, and a synergy/deleveraging catalyst — explicitly not for growth. Per our flagship philosophy of picking forward next-exponentials over trailing/mature names, AMCR is off-thesis for the exponential sleeve.
5. Financials (real numbers — FMP annual/quarterly + the 8-K)
Read these with the merger discontinuity in mind — annual FY25 is pre-Berry, recent quarters are combined:
Revenue (combined run-rate): FY26 Q1 $5.75B · Q2 $5.45B · Q3 $5.91B (+77% YoY, driven by Berry). Nine-month FY26 net sales $17.1B, +72%. Trailing combined revenue ~$22.2B. On a like-for-like basis, though, volumes were ~1.5% lower YoY — the growth is acquired.
Margins: gross ~18% TTM (thin, typical of packaging); adjusted EBITDA margin 15.1% in Q3, up from 14.3% — synergies are lifting margins, a genuine positive. Net margin ~3% TTM on GAAP (depressed by acquisition costs).
Earnings: GAAP Q3 net income $278M, diluted EPS $0.60; adjusted EPS $0.96, +6%. Nine-month adjusted EPS $2.79, +11%. GAAP TTM EPS is distorted low (a Q4'25 loss on merger charges); adjusted ~$4 is the number that matters.
Synergies: $77M realized in Q3 (upper end of expectations); FY26 target $270M pre-tax from the Berry deal — the core value-creation lever.
Cash flow: FY26 has run a small free-cash outflow nine-months in ($93M) due to ~$262M of transaction/restructuring/integration costs — normal for year-one of a mega-merger. Management guides full-year FCF $1.5–1.6B (cut from $1.8–1.9B on higher inventory to protect service levels). Watch FCF conversion normalize in FY27 as one-time costs roll off — that is the key tell.
Balance sheet:net debt $14.27B (Q3), net-debt/EBITDA ~4.9× TTM — elevated, the direct cost of the all-stock-plus-assumed-debt Berry deal. Current ratio 1.44×, interest coverage ~2.3×. Deleveraging is the multi-year job; this leverage is the single biggest reason the risk score is 6, not 4.
6. Valuation — priced in or room?
AMCR is genuinely cheap on forward earnings, and cheap for identifiable reasons. On management's FY26 adjusted-EPS guidance ($3.98–$4.03), the stock trades at ~11.3× FY26E and ~10.4× FY27E (consensus $4.33) — roughly half a typical S&P multiple. EV/EBITDA is 11.7×, EV/sales 1.6×, price/sales 0.94×, price/book 1.8×. FCF yield normalizes to a healthy high-single-digit once integration costs roll off. The FMP letter rating is B- (overall quant score 2/5, dinged hardest on debt-to-equity 1/5 and ROE/ROA 2/5) — a fair machine read: cheap but leveraged and low-return.
The bear's case on valuation is that the discount is deserved: ~4.9× leverage, flat-to-negative organic volume, thin 18% gross margins, and a dividend payout that only looks safe on adjusted EPS (on trailing GAAP EPS the payout ratio is >100%). The bull's case is that ~11× for a de-levering global #1/#2 packager throwing off a 5.75% yield is too cheap, and any synergy-driven margin lift or multiple re-rate toward 13× is meaningful upside.
Street targets (context): consensus $47.75, high $54, low $41 (9 Buy · 2 Hold · 2 Sell). Our ~$48 base-case FV sits right on consensus — we have no differentiated expert edge here, so we anchor to the numbers. Not a growth buy; a cheap, high-yield, leveraged-turnaround value name.
7. Technicals (from the tech block)
Trend: constructive but extended. $45.00 sits above the 50-DMA ($39.54) and 200-DMA ($41.68), with the 50 having crossed back above the 200 — a recovering posture. MACD +1.30 (positive).
Location:−11.0% off the 52-week high ($50.58), +22.6% off the 52-week low ($36.69). Note the max drawdown from peak was −33% — this stock can fall hard.
Momentum:RSI(14) 82 — overbought (>70). This is a clear stretched-entry warning: the recent bounce has run hot and a pullback/consolidation is the higher-probability near-term path. Do not chase here.
Relative strength (the tell): AMCR is +10.6% 3-mo (vs SPY +13.7%, QQQ +22.0%) but −5.0% over 12 months while SPY is +20.6% and QQQ +30.3%. A persistent laggard on the year — recent strength is a rebound within a year of underperformance, not established leadership.
Read: technicals say cheap-and-recovering but overbought right now. No urgency to buy; if the fundamental case appeals, waiting for RSI to cool and price to settle toward the rising 50-DMA (~$40) is the lower-risk entry.
8. Moat & competitive position
Amcor's moat is scale and switching costs, not pricing power. As the global #1/#2 in flexible packaging (materially reinforced by Berry), it wins on: (1) global manufacturing footprint close to blue-chip CPG/food/pharma customers who value supply reliability; (2) switching costs — packaging is spec'd into a customer's product, qualification is slow, and healthcare/pharma packaging is regulated and sticky; (3) scale in procurement and R&D (sustainable/recyclable packaging is a real product-development front and a regulatory tailwind). The weaknesses are structural: thin ~18% gross margins, raw-material (resin/film) and FX exposure, and end-market cyclicality tied to consumer volumes. This is a good business, not a great one — a wide-but-shallow moat.
Peer set (FMP-provided, market cap). The genuinely comparable packaging peers: Ball Corp $16.9B (metal beverage cans), International Paper $20.5B, Packaging Corp of America $21.2B, Smurfit Westrock $24.1B (all paper/containerboard). (The list also returns non-packaging Consumer-Cyclical names — Best Buy, Casey's, Dick's, Genuine Parts, IHG, Ralph Lauren — which share the sector tag but are not operating comps; ignore them for competitive read.) Against the true packaging comps, AMCR trades at a similar-to-slightly-cheap EV/EBITDA with more leverage and the added synergy optionality.
9. Management, capital allocation & guidance
Leadership & capital allocation: CEO Peter Konieczny is steering the year-one Berry integration. Capital priorities are explicit and appropriate for the situation: (1) fund the dividend (raised to 65.0¢/quarter, a ~5.75% yield — a point of board pride and a signal, but a constraint given leverage); (2) deliver Berry synergies ($270M FY26 target, $77M realized in Q3); (3) deleverage the ~4.9× balance sheet; (4) portfolio optimization — six divestiture agreements reached to prune non-core lines. Buybacks are minimal and correctly subordinated to debt paydown.
Insider activity: the sampled Form 4s are routine award/vest/withhold activity (RSU grants, in-kind tax withholding), e.g. officer grants dated 2026-06-15 — no cluster of alarming discretionary open-market selling in the window. Neutral signal.
Management's own guidance (the earnings-call track — half-weighted, self-interested by design): the SEC 8-K (Item 2.02) earnings release dated 2026-05-06 is a real earnings release and states clear forward guidance. For fiscal 2026 (ends June 30, 2026): Adjusted EPS ~$3.98–$4.03 (~12% growth at the midpoint, including $270M of Berry synergy benefits) and Free Cash Flow $1.5–1.6B (cut from $1.8–1.9B, attributed to holding higher inventory to protect customer service amid Middle-East-conflict disruption). CEO Konieczny framed year one as "a smooth integration… meaningful progress on synergy delivery and portfolio optimization." Treat as management's own book: directionally useful, weighted at 0.5. The guidance cut on FCF is the honest flag — cash conversion is running behind plan.
10. Catalysts & what to watch
Next earnings: 2026-08-13 (FY26 Q4 / full-year; Street EPS ~$1.20 for the quarter, ~$4.00 full-year adjusted). Confirm the FY26 adj-EPS guide landed and get the first FY27 outlook. (FMP also lists an 2026-08-19 estimate row; the 08-13 date is the earlier/primary consensus print.)
Berry synergy delivery: run-rate vs the $270M FY26 target and the multi-year path — the core value lever.
Deleveraging: net-debt/EBITDA trending down from ~4.9× — the gating item for a re-rate.
FCF normalization: integration/transaction costs rolling off so FCF converts back toward $1.5B+ cleanly in FY27.
Organic volume inflection: the ~1.5% YoY volume decline turning positive would change the growth read.
Dividend safety: payout must be comfortably covered by adjusted FCF as one-time costs fade.
Thesis tripwires (what would change the call): two consecutive quarters of synergy shortfall or margin backslide; leverage failing to decline; a dividend-coverage scare; or an organic-volume down-leg deep enough to threaten the deleveraging math. An upgrade to Buy — Tactical would need visible synergy delivery + deleveraging traction + a cooled-off (non-overbought) entry.
11. Key risks
Integration risk (structural, #1): merging two ~$10B+ packaging companies is hard; synergy slippage or operational disruption is the primary threat, and it is happening while leverage is high.
Leverage (~4.9× net-debt/EBITDA): amplifies every downside — a cyclical or FX shock hits equity harder, and it constrains the dividend and buyback.
Cyclicality & thin margins: ~18% gross margin leaves little cushion; consumer-volume softness (already showing as −1.5% YoY) flows quickly to earnings.
Dividend dependence: a large part of the total-return thesis is the ~5.75% yield; on GAAP trailing EPS the payout exceeds 100%, so a cash-flow disappointment puts the dividend narrative at risk.
Raw-material / FX: resin and film input costs and a global revenue base create margin and translation volatility.
No expert corroboration: unlike our conviction-track names, no tracked voice is underwriting this — the call rests solely on the numbers, which is itself a (modest) risk flag.
12. Verdict, position sizing & monitoring
Watch. Amcor is a legitimately cheap (~11× forward adjusted EPS, ~5.75% yield), globally-diversified packaging leader in the middle of a large, potentially value-creating merger. But the growth is acquired, not organic (volumes −1.5% YoY), the balance sheet carries ~4.9× net-debt/EBITDA, margins are thin, and no tracked expert underwrites the name. That combination — real but leveraged, cheap but low-growth, catalyzed but unproven — is the definition of Watch, not Buy. It is a value/income turnaround to monitor, not a compounder to own, and the RSI-82 overbought technical says there is no urgency.
Sizing: if an income/value investor chooses to own it, satellite-only, ≤2%, sized for the dividend and the deleveraging option — never a core position, and not on a stretched RSI. Most portfolios can pass.
Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print, with special attention to synergy run-rate, leverage trajectory, and FCF conversion. Upgrade path is Buy — Tactical on proven synergies + deleveraging + a cooler entry.
Single biggest risk: a botched Berry integration or a cyclical volume leg-down while carrying ~4.9× net-debt/EBITDA.
This verdict is logged as a tracked Synthos call as of 2026-07-03 at $45.00.
Provenance & disclosures
Traceability:0 KB claims — Amcor has no expert coverage in the Synthos knowledge base. No claim_ids are cited because none exist; fabricating conviction is structurally impossible and we decline to imply expert endorsement. This note is fundamentals- and quant-driven.
Data as-of: fundamentals 2026-03-31 (FY26 Q3) · estimates & prices 2026-07-02/03 · management guidance from the SEC 8-K dated 2026-05-06. Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates.
Merger & split caveat: figures span the April-30-2025 Berry Global merger (legacy Amcor = accounting acquirer, so annual FY25 is only ~2 months combined) and a 1-for-5 reverse stock split (Jan 14, 2026). Per-share and growth figures must be read with that discontinuity in mind. Adjusted (non-GAAP) EPS is used where it better reflects run-rate economics; GAAP is depressed by acquisition/integration charges.
Management caveat: management's FY2026 guidance is its own self-interested book, half-weighted by design.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").